MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Marijuana's Impact on Alcohol Motivation and Consumption

Phase 2
Completed
Conditions
Marijuana
Alcohol Drinking
Interventions
First Posted Date
2016-12-06
Last Posted Date
2021-09-28
Lead Sponsor
Brown University
Target Recruit Count
131
Registration Number
NCT02983773
Locations
🇺🇸

Brown University, Providence, Rhode Island, United States

A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking

Phase 1
Completed
Conditions
Tobacco Use
Interventions
First Posted Date
2016-11-10
Last Posted Date
2019-10-02
Lead Sponsor
Battelle Memorial Institute
Target Recruit Count
9
Registration Number
NCT02961309
Locations
🇺🇸

Battelle Memorial Institute, Baltimore, Maryland, United States

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

First Posted Date
2016-06-23
Last Posted Date
2022-03-02
Lead Sponsor
Yale University
Target Recruit Count
13
Registration Number
NCT02811939
Locations
🇺🇸

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I

Phase 1
Recruiting
Conditions
Cannabis
Interventions
Drug: Placebo
First Posted Date
2016-06-23
Last Posted Date
2024-08-13
Lead Sponsor
Yale University
Target Recruit Count
40
Registration Number
NCT02811510
Locations
🇺🇸

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2016-06-07
Last Posted Date
2025-05-09
Lead Sponsor
Johns Hopkins University
Target Recruit Count
84
Registration Number
NCT02792257
Locations
🇺🇸

Tufts Medical Center, Boston, Massachusetts, United States

🇺🇸

Miami Jewish Health, Miami, Florida, United States

🇺🇸

North Shore Medical Center, Salem, Massachusetts, United States

and more 2 locations

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans

Phase 1
Recruiting
Conditions
Cannabis
Interventions
Drug: Placebo
First Posted Date
2016-05-24
Last Posted Date
2024-08-13
Lead Sponsor
Yale University
Target Recruit Count
100
Registration Number
NCT02781519
Locations
🇺🇸

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD

Phase 2
Completed
Conditions
Posttraumatic Stress Disorder
Interventions
First Posted Date
2016-05-03
Last Posted Date
2023-07-12
Lead Sponsor
Multidisciplinary Association for Psychedelic Studies
Target Recruit Count
80
Registration Number
NCT02759185
Locations
🇺🇸

Scottsdale Research Institute, Phoenix, Arizona, United States

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

Phase 1
Active, not recruiting
Conditions
Cannabis
Alcohol Effect
Driving Under the Influence of Alcohol and Other Drugs
Interventions
First Posted Date
2016-03-16
Last Posted Date
2025-04-09
Lead Sponsor
Yale University
Target Recruit Count
40
Registration Number
NCT02710331
Locations
🇺🇸

Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, United States

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I

Phase 1
Active, not recruiting
Conditions
Cannabis
Driving Under the Influence of Alcohol and Other Drugs
Alcohol Effect
Interventions
First Posted Date
2016-03-16
Last Posted Date
2025-04-15
Lead Sponsor
Yale University
Target Recruit Count
40
Registration Number
NCT02709954
Locations
🇺🇸

Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, United States

The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia

Phase 2
Withdrawn
Conditions
Vomiting
Familial Dysautonomia
Nausea
Interventions
Other: Placebo
First Posted Date
2015-11-20
Last Posted Date
2019-06-13
Lead Sponsor
NYU Langone Health
Registration Number
NCT02608931
Locations
🇺🇸

NYU Medical Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath